Bob T. Li, MD, PhD, MPH, discusses the efficacy of sotorasib in patients with KRAS G12C–mutated advanced non-small cell lung cancer, as demonstrated in phase 2 cohort results of the phase 2 CodeBreaK 100 trial.
Bob T. Li, MD, PhD, MPH, co-director of the Thoracic Liquid Biopsy Program and physician ambassador to China and Asia-Pacific, Bobst International Center at Memorial Sloan Kettering Cancer Center, discusses the efficacy of sotorasib (AMG 510) in patients with KRAS G12C–mutated advanced non-small cell lung cancer (NSCLC), as demonstrated in phase 2 cohort results of the phase 2 CodeBreaK 100 trial (NCT03600883).
In this trial, investigators doubled down on inhibiting KRAS G12C with sotorasib, says Li. The trial accrued 126 patients with advanced-stage, refractory KRAS G12C–mutant NSCLC, Li says. Each patient received the full dose of oral sotorasib at 960 mg once daily.
Results showed an overall response rate of 37.1%, a disease control rate of 80.6%, and tumor shrinkage in approximately 80% of patients, Li notes. The median progression-free survival was 6.8 months with the agent, while the median duration of response was 10 months, which validates data from the phase 1 trial and confirms that this drug is active in this patient population, Li concludes.